[HTML][HTML] Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Background Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR)
prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral …
prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral …
Patient barriers to and enablers of deprescribing: a systematic review
…, J To, I Hendrix, S Shakib, MS Roberts, MD Wiese - Drugs & aging, 2013 - Springer
Background Inappropriate medication use is common in the elderly and the risks associated
with their use are well known. The term deprescribing has been utilised to describe the …
with their use are well known. The term deprescribing has been utilised to describe the …
Review of deprescribing processes and development of an evidence‐based, patient‐centred deprescribing process
…, I Hendrix, MS Roberts, MD Wiese - British journal of …, 2014 - Wiley Online Library
Inappropriate use of medication is widespread, especially in older people, and is associated
with risks, including adverse drug reactions, hospitalization and increased mortality. …
with risks, including adverse drug reactions, hospitalization and increased mortality. …
[HTML][HTML] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal …
A Rowland, MM Dias, MD Wiese… - British journal of …, 2015 - nature.com
Background: Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF
MT) is associated with poorer outcomes. However, whether this mutation is predictive of …
MT) is associated with poorer outcomes. However, whether this mutation is predictive of …
People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe
E Reeve, MD Wiese, I Hendrix… - Journal of the …, 2013 - Wiley Online Library
Objectives To capture people's attitudes, beliefs, and experiences regarding the number of
medications they are taking and their feelings about stopping medications. Design …
medications they are taking and their feelings about stopping medications. Design …
Clinical outcomes associated with medication regimen complexity in older people: a systematic review
…, AJ Cross, N Jokanovic, MD Wiese… - Journal of the …, 2017 - Wiley Online Library
Objectives To systematically review clinical outcomes associated with medication regimen
complexity in older people. Design Systematic review of EMBASE , MEDLINE , International …
complexity in older people. Design Systematic review of EMBASE , MEDLINE , International …
[HTML][HTML] Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
…, A Rowland, G Kichenadasse, MD Wiese… - British journal of …, 2017 - nature.com
Immune checkpoint inhibitors (ICI) are an important development in the treatment of
advanced cancer. A substantial proportion of patients treated with ICI do not respond, and …
advanced cancer. A substantial proportion of patients treated with ICI do not respond, and …
Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study
…, JS Bell, J Fastbom, MD Wiese… - Annals of …, 2016 - journals.sagepub.com
Objectives: To investigate whether medication regimen complexity and/or polypharmacy are
associated with all-cause mortality in older people. Methods: This was a population-based …
associated with all-cause mortality in older people. Methods: This was a population-based …
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated …
…, A Rowland, RA McKinnon, MD Wiese - Circulation …, 2014 - Am Heart Assoc
… Wiese) with any discrepancies resolved by the other investigators (M. Sorich and R. … Sorich
MJ, Polasek TM, Wiese MD . Challenges and limitations in the interpretation of systematic …
MJ, Polasek TM, Wiese MD . Challenges and limitations in the interpretation of systematic …
[PDF][PDF] The benefits and harms of deprescribing
…, S Shakib, I Hendrix, MS Roberts, MD Wiese - Medical journal of …, 2014 - mja.com.au
… Michael D Wiese … 17 Reeve E, Wiese MD. Benefits of deprescribing on patients’
adherence to medications. Int J Clin Pharm 2014; 36: 26-29. 18 Reeve E, Wiese MD …
adherence to medications. Int J Clin Pharm 2014; 36: 26-29. 18 Reeve E, Wiese MD …